‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒
‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including GLP-2 and Human Growth Hormone ‒
‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒
BOSTON and JERUSALEM, May 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the quarter ended March 31, 2021.
First Quarter 2021 and Recent Highlights
- 3-Month Primary Efficacy Endpoint Achieved in Phase 2 Trial of EB613 in Osteoporosis: EB613, an orally delivered human parathyroid hormone (1-34) or PTH, is positioned to be the first oral bone building (osteoanabolic) treatment for osteoporosis. The Phase 2 study’s efficacy endpoints include an evaluation of biomarker data after 3 and 6 months of treatment and bone mineral density data (BMD) after 6 months of treatment. The study met its primary 3-month endpoint. Subjects in the 2.5 mg dose group had a significant (p